comparemela.com

Latest Breaking News On - Tumour group - Page 1 : comparemela.com

Nuvectis Pharma Announces Positive Data for NXP900 in a Preclinical Model of Group 4 Medulloblastoma, A Type of Brain Cancer That Affects Predominantly Pediatric Patients

13.06.2022 - FORT LEE, N.J., June 13, 2022 (GLOBE NEWSWIRE) - Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need . Seite 1

Gateway for Cancer Research funds EORTC 1634-BTG trial in post-pubertal brain tumor patients

Gateway for Cancer Research funds EORTC 1634-BTG trial in post-pubertal brain tumor patients Gateway for Cancer Research℠ awards grant to the EORTC 1634- Brain Tumour Group (BTG) academic trial in Post-Pubertal Patients with Newly-Diagnosed Medulloblastoma (PersoMed-I). Medulloblastoma is a rare brain tumor. In the US, it affects 550 adults, and in Europe around 450 adults annually, with the majority being young adults. Adolescent and adult medulloblastomas are biologically distinct in comparison to pediatric medulloblastomas, which mandates age adapted treatment strategies. Adolescent patients all bear an intermediate to high prognostic risk, leading to poor patient survival and disability. We are still unaware of the most effective treatment with the lowest possible rate of side effects (long-term toxicity) for this age group.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.